J. VIDHIYASAGARAN
Post graduate, MD pharmacology 2H.O.D cardiology dept., PSGIMSR 3H.O.D pharmacology dept., PSGIMSR
Abstract
The aim of the present study is to identify clinical indications for Ivabradine use in cardiovascular ischemic disorders in tertiary hospital, to identify the clinical benefits of Ivabradine using clinical parameter like echo and to observe any Adverse Drug Reaction during Ivabradine therapy in Ischemic Heart Disease treatment. Ischemic heart disease patients who are attending cardiology dept for their regular follow up were selected based on inclusion and exclusion criteria after obtaining informed consent. Ethical clearance got from human ethics committee institutional board. Quality of life with Ivabradine is assessed using preformed questionnaire both prospectively (6 months) and retrospectively(1 year) using Canadian Cardiovascular Society angina grading scale and New York Heart Association (NYHA) functional classification for heart failure with complete cardiac investigations during first clinical examination and 3,6 months later.. Quality of life is improved as per questionnaire. Ejection fraction is improved clinically and there is statistical significance (p<0.05). Left ventricular thickness and mass is reduced clinically but there is no statistical significance (p>0.05). Ivabradine is a safe anti anginal drug as it reduced post systolic wall thickening and prevented cardiac remodeling, without any adverse drug reaction of its own or drug interaction with polypharmacy and therefore can be prescribed for patients with various ischemic heart diseases.
Key words: Ivabradine, left ventricular thickness, left ventricular mass, Ejection fraction.